Medpace (NASDAQ:MEDP) CEO August Troendle Sells 1,983 Shares

Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August Troendle sold 1,983 shares of the company’s stock in a transaction on Monday, August 24th. The stock was sold at an average price of $620.23, for a total value of $1,229,916.09. Following the transaction, the chief executive officer directly owned 545,217 shares in the company, valued at approximately $338,159,939.91. This represents a 0.36% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Medpace Stock Performance

NASDAQ MEDP opened at $614.06 on Wednesday. The stock has a fifty day moving average of $556.26 and a 200-day moving average of $492.77. The stock has a market capitalization of $17.14 billion, a P/E ratio of 35.99, a price-to-earnings-growth ratio of 2.77 and a beta of 1.15. Medpace Holdings, Inc. has a 52 week low of $373.00 and a 52 week high of $677.90.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.98 by $0.27. The business had revenue of $707.33 million for the quarter, compared to analyst estimates of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The firm’s revenue for the quarter was up 17.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $3.10 earnings per share. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Equities research analysts forecast that Medpace Holdings, Inc. will post 17.54 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on MEDP. Mizuho raised their target price on shares of Medpace from $586.00 to $665.00 and gave the company an “outperform” rating in a research note on Friday, July 24th. Royal Bank Of Canada boosted their price target on shares of Medpace from $484.00 to $692.00 and gave the stock an “outperform” rating in a research note on Friday, July 24th. Robert W. Baird increased their price objective on shares of Medpace from $547.00 to $624.00 and gave the company a “neutral” rating in a report on Friday, July 24th. TD Cowen raised their price objective on shares of Medpace from $419.00 to $492.00 and gave the company a “hold” rating in a research note on Friday, July 24th. Finally, Truist Financial lifted their target price on shares of Medpace from $462.00 to $609.00 and gave the stock a “hold” rating in a report on Friday, July 24th. Three analysts have rated the stock with a Buy rating and ten have given a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $584.18.

Medpace News Roundup

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: Medpace’s latest quarterly results were strong: earnings of $4.25 per share exceeded the $3.98 consensus estimate, while revenue rose 17.2% year over year to $707.33 million, ahead of expectations. Management’s fiscal 2026 EPS guidance is $17.25–$17.95. Institutional ownership is also high at approximately 78%, with several large investors adding positions.
• Neutral Sentiment: Reported short interest was listed at zero shares, with a zero-day days-to-cover ratio. Because the figures show no measurable short position, they provide little indication of near-term buying or selling pressure.
• Neutral Sentiment: Analyst sentiment remains mixed. The consensus rating is “Hold,” with an average price target of $584.18, below recent trading levels. BMO Capital Markets raised its target to $600 while maintaining a market-perform rating, and Weiss Ratings upgraded the stock to “Buy.”
• Negative Sentiment: Multiple company insiders recently sold shares. CEO August J. Troendle sold 13,995 shares for approximately $8.74 million on August 21 and another 1,983 shares for about $1.23 million on August 24. CFO Kevin Brady sold 3,400 shares worth roughly $2.13 million, reducing his ownership by 20.95%. Additional director sales were also reported. Although executives retain significant holdings, the concentration of selling can weigh on investor confidence.

Hedge Funds Weigh In On Medpace

Several institutional investors have recently modified their holdings of the stock. Johnson Financial Group Inc. bought a new position in Medpace during the 2nd quarter worth approximately $27,000. Geneos Wealth Management Inc. increased its stake in Medpace by 64.9% in the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after purchasing an additional 37 shares in the last quarter. Elyxium Wealth LLC acquired a new stake in Medpace in the fourth quarter worth $30,000. Jones Financial Companies Lllp bought a new position in shares of Medpace during the 2nd quarter valued at about $30,000. Finally, Allied Private Wealth LLC acquired a new position in shares of Medpace in the second quarter valued at approximately $31,000. 77.98% of the stock is currently owned by institutional investors and hedge funds.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.